Skip to main content
VVOS
NASDAQ Industrial Applications And Services

Michael Skaff Reveals 19.9% Vivos Stake Following $1.6M Preferred Stock Investment

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$0.42
Mkt Cap
$5.737M
52W Low
$0.383
52W High
$7.03
52W Position info
9.7% above low
Off High info
94% below high
Rel. Volume
Market data snapshot near publication time

VVOS is trading near its 52-week low of $0.383 (9.7% above the low).

Summary

Michael Skaff's V-Co entities now hold 19.9% of Vivos Therapeutics after a $1.6M preferred stock and warrant purchase, injecting vital capital into a company confronting going concern and Nasdaq delisting risks.


Key Events · Ownership and Investor Activity · VVOS

  • Skaff Acquires 19.9% Stake

    On June 30, 2026, Michael Skaff and his V-Co entities disclosed beneficial ownership of 2,783,102 shares, or 19.9%, following a $1.6M private placement of Series A Convertible Preferred Stock and warrants by V-Co 4.

  • Placement Priced at Premium

    The preferred stock was acquired at $0.582 per share—a premium to the current $0.42 market price—with warrants exercisable at $0.456 per share. Of the $1.6M total, $1.1M was funded by converting an existing note.

  • Potential Control Exceeds 50%

    Absent the 19.99% beneficial ownership blocker, Skaff's group could control an additional 18.4 million shares through warrants and preferred conversion, representing over 50% of the company.

  • Capital Infusion Amid Distress

    The investment delivers critical funding as Vivos contends with a going concern warning, Nasdaq non-compliance for minimum equity, and a cash balance of just $1.2M as of Q1 2026.


Analysis · VVOS · Industrial Applications And Services

Through his V-Co entities, Michael Skaff has secured a 19.9% beneficial ownership in Vivos Therapeutics via a $1.6 million private placement of convertible preferred stock and warrants. Priced at $0.582 per share—a premium to the current $0.42 stock price—the deal includes a blocker capping ownership at 19.99%, yet without it, Skaff's group could command over 50% of the company. The investment arrives as Vivos grapples with a going concern warning, Nasdaq non-compliance, and a precarious cash position, making this both a critical lifeline and a significant concentration of influence in one investor's hands.

At the time of this filing, VVOS was trading at $0.42 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $5.7M. The 52-week trading range was $0.38 to $7.03. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

VVOS - Latest Insights

VVOS
Jul 15, 2026, 5:07 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
VVOS
Jul 15, 2026, 4:23 PM EDT
Filing Type: 4
Importance Score:
8
VVOS
Jul 07, 2026, 5:33 PM EDT
Source: Wiseek News
Importance Score:
8
VVOS
Jul 07, 2026, 5:29 PM EDT
Filing Type: 8-K
Importance Score:
8
VVOS
Jun 30, 2026, 8:45 AM EDT
Source: GlobeNewswire
Importance Score:
9
VVOS
Jun 25, 2026, 5:23 PM EDT
Source: Wiseek News
Importance Score:
8
VVOS
Jun 25, 2026, 5:22 PM EDT
Filing Type: 8-K
Importance Score:
8
VVOS
Jun 22, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
VVOS
Jun 16, 2026, 5:03 PM EDT
Filing Type: 8-K
Importance Score:
8
VVOS
Jun 15, 2026, 7:44 PM EDT
Filing Type: 8-K
Importance Score:
8